Connection

Co-Authors

This is a "connection" page, showing publications co-authored by CARLOS E BUESO-RAMOS and MARK J ROUTBORT.
Connection Strength

1.847
  1. Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 May; 35(5):705.
    View in: PubMed
    Score: 0.209
  2. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Mod Pathol. 2022 04; 35(4):470-479.
    View in: PubMed
    Score: 0.203
  3. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
    View in: PubMed
    Score: 0.170
  4. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 2016 Mar 22; 7(12):14251-8.
    View in: PubMed
    Score: 0.137
  5. Preleukemic phase of chronic myelogenous leukemia: morphologic and immunohistochemical characterization of 7 cases. Ann Diagn Pathol. 2016 Apr; 21:53-8.
    View in: PubMed
    Score: 0.136
  6. Therapy-Related Myeloid Neoplasms. Am J Clin Pathol. 2015 Aug; 144(2):207-18.
    View in: PubMed
    Score: 0.131
  7. High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei). Blood. 2006 Sep 01; 108(5):1783-4.
    View in: PubMed
    Score: 0.071
  8. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.
    View in: PubMed
    Score: 0.056
  9. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.053
  10. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. 2022 09; 35(9):1212-1219.
    View in: PubMed
    Score: 0.052
  11. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer. 2021 10 01; 127(19):3552-3565.
    View in: PubMed
    Score: 0.049
  12. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
    View in: PubMed
    Score: 0.048
  13. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw. 2020 10; 18(10):1300-1304.
    View in: PubMed
    Score: 0.047
  14. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.
    View in: PubMed
    Score: 0.045
  15. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.045
  16. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
    View in: PubMed
    Score: 0.041
  17. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One. 2018; 13(9):e0204218.
    View in: PubMed
    Score: 0.041
  18. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
    View in: PubMed
    Score: 0.040
  19. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
    View in: PubMed
    Score: 0.040
  20. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017 10; 102(10):1661-1670.
    View in: PubMed
    Score: 0.037
  21. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.
    View in: PubMed
    Score: 0.035
  22. Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol. 2016 03; 145(3):418-27.
    View in: PubMed
    Score: 0.034
  23. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol. 2016 Apr; 50:109-17.
    View in: PubMed
    Score: 0.034
  24. Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol. 2015 Aug; 95(2):168-76.
    View in: PubMed
    Score: 0.032
  25. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.031
  26. Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. Mod Pathol. 2013 Oct; 26(10):1338-45.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.